Surantel P Horse Wormer 40% w/w Oral Paste

Land: Vereinigtes Königreich

Sprache: Englisch

Quelle: VMD (Veterinary Medicines Directorate)

Wirkstoff:

Pyrantel Embonate

Verfügbar ab:

Cross Vetpharm Group Ltd

ATC-Code:

QP52AF02

INN (Internationale Bezeichnung):

Pyrantel Embonate

Darreichungsform:

Oral paste

Verschreibungstyp:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Therapiegruppe:

Horses

Therapiebereich:

Anthelmintic

Berechtigungsstatus:

Authorized

Berechtigungsdatum:

2003-09-05

Fachinformation

Amended pages
Revised: January 2017
S U MM AR Y O F P R O DUC T C H ARACTER IS T I CS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Surantel P Horse Wormer Oral Paste 40% w/w
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance
Per Syringe
%w/w
Pyrantel embonate
11.4g
40.00
Excipients
Butylated Hydroxytoluene
0.0057g
0.02
For full list of excipients, please see section 6.1
3.
PHARMACEUTICAL FORM
Oral Paste
Pale yellow to buff colored paste
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and ponies
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Pyrantel embonate is a broad spectrum anthelmintic. Pyrantel embonate
is indicated for use in the horse for the control and treatment of
adult
infections of large and small strongyles, Pinworms, Roundworms,
Tapeworms.
Pyrantel embonate has a broad spectrum of activity, including activity
against:
Large strongyles:
Stronglylus vulgaris, S. edentatus, S.
equinus.
Small strongyles:
Trichonema spp. (Cyathostomes),
Triodontophorus spp.
Pinworms:
Oxyuris equi, Probstmayria vivipara.
Large roundworms:
Parascaris equorum.
Tape worms:
Anoplocephala perfoliata.
4.3
CONTRA-INDICATIONS
Not for use in foals less than 4 weeks of age.
Contraindicated in known sensitivity to pyrantel and in severely
debilitated
animals.
Amended pages
Revised: January 2017
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES.
Care should be taken to avoid the following practices because they
increase the risk of development of resistence and could ultimately
result in
ineffective therapy:

Too frequent and repeated use of anthelmintics from the same
class, over an extended period of time.

Under dosing, which may be due to underestimation of weight,
misadministration of the product, or lack of calibration of the dosing
device
(if any).
Suspected clinical cases of resistence to anthelmintics should be
further
investigated using appropriate tests (e.g. Faecal Egg Count Reduction
Test). Where the results of the test(s) strongly suggest resistance to
a
particular
anthelminitc,
an
anthelmintic
belo